Pravastatin concentrations in maternal serum, umbilical cord serum, breast milk and neonatal serum during pregnancy and lactation: A case study
Funding information
This work was supported by The Japan Agency for Medical Research and Development (JP19mk0101086h0003), awarded to AM
Abstract
What is known and objective
Statins are associated with improved pregnancy outcomes in patients with preeclamptic antiphospholipid syndrome (APS) and intrauterine foetal death. Several studies showed that statins are not teratogenic. However, data characterizing placental transfer and excretion of pravastatin into breast milk are limited.
Case summary
We experienced two patients diagnosed with APS received 10 mg of pravastatin from the first trimester until delivery to prevent pre-eclampsia. Pravastatin concentrations in maternal serum, infant serum and cord blood were evaluated. The estimated maternal-foetal transfer ratios of pravastatin in the two patients were 25.5% and 23.8% respectively. Pravastatin was eliminated from neonatal serum within 2 days. Both infants developed normally with no drug-related adverse effects. Pravastatin was not detected in either patient's breast milk at 3 days after the last dose.
What is new and conclusion
The infants delivered from the mothers who were treated with pravastatin during pregnancy had no apparent adverse effects.
CONFLICTS OF INTEREST
All authors declare no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
Data is available on request from the author.
